AstraZeneca
The September 2018 issue of Pharmafocus is available to read online now!
September 3, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, AstraZeneca, Cancer, Iraw, J&J, JJ, Pfizer, Roche, UK, brexit, drug safety, pharma, pharmacovigilance
The new September edition of Pharmafocus is now live and available to read online. We’re entering the final stretch as …
Top Ten most popular articles on Pharmafile.com this week
August 31, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Medicare, Novartis, UK, brexit, generics, king bio, pharma, top ten
Eight months of 2018 down – where has the year gone? As we move from August into September, and a …
AZ’s lupus drug fails to curb lupus activity at Phase 3
August 31, 2018Medical Communications, Research and Development AstraZeneca, Lupus, anifrolumab, pharma
AstraZeneca and its biologics R&D arm MedImmune have released a statement admitting that their fully human monoclonal antibody anifrolumab failed …
AstraZeneca’s once-weekly auto-injector Bydureon BCise wins EU approval in type 2 diabetes
August 30, 2018Research and Development, Sales and Marketing AstraZeneca, Bydureon, EU, Europe, diabetes, pharma, type 2 diabetes
AstraZeneca has announced that its auto-injector Bydureon BCise (exenatide 2mg prolonged-release suspension) has been approved by the European Commission for …
AstraZeneca shocked as inhaler fails to outclass GSK rival in COPD
August 23, 2018Research and Development AstraZeneca, COPD, GSK, anoro, inhaler, pharma
Researchers at AstraZeneca have been left scratching their heads as new Phase 3b results for its inhaler, Bevespi Aerosphere, posted …
Japan approves AstraZeneca’s Tagrisso in EGFRm non-small cell lung cancer
August 21, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, Japan, Tagrisso, lung cancer, pharma
AstraZeneca has revealed that its EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) has been approved in Japan by the nation’s Ministry …
AstraZeneca to pay $110m to settle allegations of fraudulent marketing in Texas
August 8, 2018Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Texaas, US, pharma
AstraZeneca has backed down in a dispute with the State of Texas over allegations it had defrauded the state’s Medicaid …
Ironwood returns US Zurampic rights to AstraZeneca, announces operational cuts
August 7, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Ironwood, Zurampic, gout, pharma
Ironwood Pharmaceuticals has revealed that it has taken the decision to hand the rights for gout therapy Zurampic (lesinurad) back …
Lawsuit alleges pharma giants funded terror in Iraq
August 2, 2018Business Services, Medical Communications, Sales and Marketing AstraZeneca, Iraq War, J&J, JJ, Litigation, Roche, corruption, terrorism
The United States Justice Department is investigating claims that major pharmaceutical and medical device companies were aware that supplies that …
AstraZeneca announces price freezes while earnings drop by 28%
July 26, 2018Business Services, Sales and Marketing AstraZeneca, Trump, price freezes, price hikes
The Anglo-Swedish drug maker AstraZeneca has joined Pfizer and others in halting price hikes until the end of 2018. AstraZeneca …
AstraZeneca jettisons European heart drug rights for $210m
July 24, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Atacand, Cheplapharm, blood pressure, heart failure, pharma
AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment …
AstraZeneca increases drug stockpile in preparation for no-deal Brexit
July 18, 2018Research and Development AstraZeneca, brexit, no-deal, pharma, stockpiling
The Anglo-Swedish drug giant AstraZeneca is set to increase its stockpile of drugs in both the United Kingdom and the …
AstraZeneca chalks up double Japanese approval in lung and breast cancer
July 2, 2018Sales and Marketing AstraZeneca, Cancer, Imfinzi, NSCLD, breast cancer, lung cancer, lynparza, pharma
It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have …
AstraZeneca’s Lynparza proves efficacy in first-line BRCA-mutated advanced ovarian cancer
June 27, 2018Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, Merck, ovarian cancer, pharma
AstraZeneca is celebrating alongside partner MSD with the reveal of new data on the use of Lynparza in the first-line …
Pfizer’s Ibrance combo fails to improve overall survival in HER2- metastatic breast cancer
June 26, 2018Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Faslodex, Pfizer, breast cancer, ibrance, pharma
Pfizer has stumbled with the reveal of new data on the efficacy of its oral CDK 4/6 inhibitor Ibrance (palbociclib) in combination …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
